DOK2 and adenocarcinoma: In the current study, the results demonstrated that the expression of DOK2 was downregulated in 34 colorectal cancer tissue samples from patients with poorly-differentiated adenocarcinoma, while it was expressed in all of the normal colorectal tissues, suggesting that DOK2 may be involved in the initiation and progression of colorectal cancer, in addition to the prognostic assessment.